Gabapentin-d4
(Synonyms: 加巴喷丁 d4) 目录号 : GC47388
An internal standard for the quantification of gabapentin
Cas No.:1185039-20-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Gabapentin-d4 is intended for use as an internal standard for the quantification of gabapentin by GC- or LC-MS. Gabapentin is a γ-aminobutyric acid (GABA) analogue that acts as an anticonvulsant.1,2,3 It does not bind to GABA receptors, does not influence neural uptake of GABA, and does not inhibit the GABA-metabolizing enzyme, GABA transaminase.4,5 Unlike GABA, which does not pass through the blood-brain barrier, gabapentin penetrates into the central nervous system and binds to the α2δ-type voltage-gated calcium channels. Formulations containing gabapentin have been used to treat neuropathic pain caused by complex regional pain syndrome type one, cancer, and HIV as well as to control dysesthesias in patients with multiple sclerosis.1,2,3
1.van de Vusse, A.C., Stonmp-van de Berg, S.G.M., Kessels, A.H.F., et al.Randomised controlled trial of gabapentin in complex regional pain syndrome type I [ISRCTN84121379]BMC Neurol.4(13)(2004) 2.Hahn, K., Arendt, G., Braun, J.S., et al.A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathiesJ. Neurol.251(10)1260-1266(2004) 3.Caraceni, A., Zecca, E., Bonezzi, C., et al.Gabapentin for neuropathic cancer pain: A randomized controlled trial from the gabapentin cancer pain study groupJ. Clin. Oncol.22(14)2909-2917(2004) 4.Gee, N.S., Brown, J.P., Dissanayake, V.U.K., et al.The novel anticonvulsant drug, gabapentin (neurontin), binds to the α2δ subunit of a calcium channelJ. Biol. Chem.271(10)5768-5776(1996) 5.Goa, K.L., and Sorkin, E.M.Gabapentin. A review of its pharmacological properties and clinical potential in epilepsyDrugs46(3)409-427(1993)
| Cas No. | 1185039-20-6 | SDF | |
| 别名 | 加巴喷丁 d4 | ||
| Canonical SMILES | NC([2H])([2H])C1(C([2H])([2H])C(O)=O)CCCCC1 | ||
| 分子式 | C9H13D4NO2 | 分子量 | 175.3 |
| 溶解度 | PBS (pH 7.2): 10 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.7045 mL | 28.5225 mL | 57.0451 mL |
| 5 mM | 1.1409 mL | 5.7045 mL | 11.409 mL |
| 10 mM | 0.5705 mL | 2.8523 mL | 5.7045 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。